Andrew Dickinson
Chief Financial Officer

Andrew Dickinson serves as Gilead's Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations.
Andy joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Andy drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Andy was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006.
Andy received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago.
-
Daniel O’Day
Chairman and Chief Executive Officer, Gilead Sciences, Inc.
-
Andrew Dickinson
Chief Financial Officer
-
Stacey Ma
Executive Vice President, Pharmaceutical Development and Manufacturing
-
Flavius Martin
Executive Vice President, Research
-
Jyoti Mehra
Executive Vice President, Human Resources
-
Johanna Mercier
Chief Commercial Officer
-
Merdad Parsey, MD, PhD
Chief Medical Officer
-
Cindy Perettie
Executive Vice President, Kite
-
Deborah H. Telman
Executive Vice President, Corporate Affairs and General Counsel